Author:
Tuffaha Muin S. A.,Guski Hans,Kristiansen Glen
Publisher
Springer International Publishing
Reference6 articles.
1. Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2:247–58.
2. Burdelski C, Jakani-Karimi N, Jacobsen F, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018;39(1):3–12.
3. Gadara MR, Gonzalez M, Cartun R, et al. IMP3 immunoreactivity is more sensitive than AMACR in detecting dysplastic epithelium and early adenocarcinoma in Barrett esophagus. Applied immunohistochemistry and molecular. Morphology. 2017;25(6):386–91.
4. Altevogt P, Sammar M, Hüser L, Kristiansen G. Novel insights into the function of CD24: a driving force in cancer. Int J Cancer. 2021;148(3):546–59.
5. Wang W, Wang X, Peng L, et al. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2010;101(1):112–9.